Ruifeng Yang

Associate Professor at Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China

Yang is focusing on the clinical laboratory diagnosis of liver diseases and infectious diseases using routine and novel molecular and serological assays. He is responsible for the laboratory quality control and accreditation programs, i.e., the ISO 15189 and the College of American Pathologists (CAP) accreditation programs. He is also partly in charge of the central laboratory operation for many multicentre national and international clinical trials for the new drugs and diagnostic assays. In his research field, Yang is interested in the methodology standardization & innovation, performance evaluation and clinical application of the infection related biomarkers, such as the quantitative HBsAg/HBeAg, HBV/HCV genotypes, HCV core antigen, and HBV core related antigens.   

Yang has a series of virus related papers (7 of which are the first author papers, with the highest IF of 4.30), an NSFC (81201339, “Methodological standardization for the hepatitis B virus drug resistance detection assays”) and a patent (201410601946.3, “A core antigen fragment used for the detection of hepatitis C virus”). He gained the second prize of the Chinese Medical Science and Technology Award at 2015 for the follow-up and treatment of the chronic hepatitis C patients. 

He is a member of the Beijing Medical Association, Hepatitis B Section since 2014. He is the editorial member of the Chinese journal of diagnostics, and he is the invited reviewer of the Chinese journal of clinical laboratory science, Clinica chimica acta, and the Journal of clinical laboratory analysis.